Given the limited treatment options and increasing prevalence of VRE in the world, VRE remains a severe problem in health care. However, this overall increase in variation has been reported in countries. The patterns of antimicrobial resistance and the prevalence of VRE were examined in Zahedan. This investigation indicated a severe problem of antimicrobial resistance among Enterococci in a hospital in Zahedan. In addition, this pathogen was recognized as a significant nosocomial pathogen causing substantial morbidity and mortality globally. Since the studies have shown the rate of VRE in Germany, the UK, and Italy were 11.2%, 8.5%, 12.5%, and 9%, respectively, in the present study, the 50% rate of VRE prevalence was in agreement with earlier reports of high VRE prevalence in other cities. According to a meta-analysis by Emaneini et al., the estimated prevalence of VRE in Iran was 9.4% (
13), whereas it was found to be 50% in the present study. The predominant location of Enterococcal infection in this investigation was the urinary tract (84.7%), frequently observed in patients. Septicemia, at 11.2%, was the subsequent most frequent infection after bacteremia. The dominant species of
Enterococcus was identified as
E. faecalis, accounting for 82% of cases, aligning with the findings of Chakraborty et al. study in India, which reported a prevalence of 80 - 90% for this bacterium in 2015 (
11). The bacteria showed high resistance to gentamicin and cephalexin, while resistance to linezolid was the least observed, and 24% of isolates were resistant to vancomycin (
8). However, this study noted a 50% resistance rate to vancomycin. In Razaz Rahmati et al., among 203
Enterococcus strains from Tehran hospitals, resistance was 47.3% to ampicillin, 24.6% to vancomycin, and 9.4% to teicoplanin, with a higher sensitivity to linezolid reported (
14). The findings for ampicillin resistance and linezolid sensitivity are consistent with these figures. Goudarzi et al. found no resistance to linezolid among 690 Enterococcal isolates (0%) (
15), whereas our study revealed a 63.9% sensitivity rate (
Figure 2), indicating a notable level of resistance. Abamecha et al. in Ethiopia found that out of 114 isolated Enterococci, 32.4% were resistant to nitrofurantoin, 49.1% to ciprofloxacin, and 36% to ampicillin, showing an increase in resistance compared to previous results (
16). Melese et al. reported that 60.7% of VRE strains were resistant to penicillin and 56.5% to amoxicillin, with a relatively low resistance of 13% to linezolid and daptomycin, which is in contrast to the high sensitivity to linezolid observed in the current study (
Figure 2) (
17). Various studies, including Devi et al. (
18), Harris et al. (
19), Karmarkar et al. (
20), Sader et al. (
21), Pancesso et al. (
22), Zhanel et al. (
23), Fernandes and Dhanashree (
24), and Mihajlović-Ukropina et al. (
25), have reported the prevalence of vancomycin resistance in Enterococcal strains to be 10%, 20%, 8.6%, 23.3%, 3.1%, 6%, 23%, 31%, and 31% respectively. According to
Figure 1, this bacteria's highest range of contamination was observed in the ICU, maternity and internal ward, which was similar in some research. In Karimzadeh et al. in Shiraz (
26), the most contamination by
Enterococcus was in the surgical and internal wards, but in Alebouyeh et al. in Tehran, the ICU ward had the highest range of contamination (
27). Enterococcal strains are a significant factor in urinary tracheal infection, and they are the third factor of UTI in hospitalized patients, particularly in maternity wards. According to De Francesco et al., in Italy, Enterococci caused 9% of positive cases in outpatients and 12% in inpatients (
26).